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Abstract Mutations in the genes encoding leucine-rich re-
peat kinase 2 (LRRK2) and α-synuclein are associated with
both autosomal dominant and idiopathic forms of Parkin-
son’s disease (PD). α-Synuclein is the main protein in Lewy
bodies, hallmark inclusions present in both sporadic and
familial PD. We show that in PD brain tissue, the levels of
LRRK2 are positively related to the increase in α-synuclein
phosphorylation and aggregation in affected brain regions
(amygdala and anterior cingulate cortex), but not in the
unaffected visual cortex. In disease-affected regions, we
show co-localization of these two proteins in neurons and
Lewy body inclusions. Further, in vitro experiments show a
molecular interaction between α-synuclein and LRRK2 un-
der endogenous and over-expression conditions. In a cell
culture model of α-synuclein inclusion formation, LRRK2
co-localizes with the α-synuclein inclusions, and knocking
down LRRK2 increases the number of smaller inclusions. In
addition to providing strong evidence for an interaction
between LRRK2 and α-synuclein, our results shed light on
the complex relationship between these two proteins in the
brains of patients with PD and the underlying molecular
mechanisms of the disease.
Keywords LRKK2 .α-Synuclein . Parkinson’s disease .
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Introduction
Parkinson’s disease (PD) is the most common neurodegen-
erative movement disorder resulting from the loss of dopa-
mine neurons in the substantia nigra and the abnormal
deposition of cytoplasmic inclusions known as Lewy bodies
and Lewy neurites in widespread regions of the brain [1].
The aetiology of PD is multifactorial, with a growing num-
ber of genetic abnormalities identified [2]. The first PD
causative gene was α-synuclein (SNCA), which encodes
for the presynaptic protein α-synuclein [3]. Rare patients
have missense mutations (A53T, A30P, and E46K) or multi-
plications of SNCA [2], but all PD patients accumulate
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phosphorylated α-synuclein in the form Lewy pathologies
[4, 5]. Leucine-rich repeat kinase 2 (LRRK2) has been
identified as the second and more common gene responsible
for autosomal-dominant PD [6–9]. The function of the large
LRRK2 protein remains unclear, although its serine–threo-
nine/tyrosine kinase function is considered most important
for PD aetiology due to the occurrence of the most common
LRRK2 mutation (G2019S) in this domain [2]. As phosphor-
ylation of α-synuclein is central to PD and the most com-
mon autosomal-dominant mutation occurs in a kinase, there
has been intense debate about whether α-synuclein physi-
cally interacts with LRRK2 and whether it might be one of
its substrates [10]. However, to date, only one report has
shown that α-synuclein interacts with, and is phosphorylat-
ed by, LRRK2 and only under pathological and non-
physiological oxidative stress conditions [11].
Co-immunoprecipitation is the gold standard for assessing
direct protein interactions but relies on antibody specificity, a
previous problem for LRRK2 antibodies that has been recent-
ly solved with the aid of resources from the Michael J. Fox
Foundation (MJFF). It is now possible to revisit the question
of a LRRK2 and α-synuclein interaction using these new and
well-characterized LRRK2 antibodies. The aim of the present
study was to establish whether LRRK2 and α-synuclein in-
teract in human brain samples and to investigate the signifi-
cance of the interaction in cell models. We report a molecular
interaction between LRRK2 and α-synuclein under endoge-
nous and over-expression conditions. We show in affected PD
brain regions that the amount of LRKK2 protein is increased
in association with increasing levels of phosphorylated α-
synuclein. At the neuronal level, we confirm co-localization
of LRRK2 andα-synuclein in Lewy bodies in PD patients and
show co-localization in a cell model of α-synuclein inclusion
formation. In addition, knockdown of LRRK2 in this cell
model increases the number but reduces the size of α-
synuclein inclusions. Altogether, our data provide strong ev-
idence for an interaction between LRRK2 and α-synuclein in
PD and opens novel avenues for the investigation of the
interplay between different PD genes and their exploitation
as targets for therapeutic intervention.
Materials and methods
Human and mouse brain samples
Human brain tissue was obtained from the Sydney Brain
Bank and the NSW Tissue Resource Centre as part of the
Australian Brain Bank Network funded by the National
Health and Medical Research Council of Australia
(NHMRC) with appropriate institutional ethics approvals.
Frozen brain tissue samples and formalin-fixed paraffin-
embedded tissue sections from different brain regions
considered to be progressively affected by α-synuclein depo-
sition in PD [12] were received from ten sporadic PD cases
and ten matched controls (see Supplementary Information).
The regions were the amygdala (affected pre-clinically in PD),
the midbrain and anterior cingulate cortex (affected when
symptoms are apparent) and the visual cortex (remains free
of α-synuclein pathology even at end-stage disease).
Crude soluble human brain proteins were extracted from
the frozen tissue as previously described [13]. Briefly, tissue
was homogenized with a pre-chilled dounce homogenizer
using ice-cold tris-buffered saline (TBS, pH7.4) lyses buffer
(LB) containing protease and phosphatase inhibitor cock-
tails (Roche, Dee Why, Australia and Thermo Fisher Scien-
tific, Waltham, MA, USA). The TBS-soluble supernatant
fraction was collected after centrifugation at 16,000×g for
25 min at 4 °C, and the pellets were solubilised in LB
containing 5 % SDS (SDS-soluble fraction). Protein con-
centration was measured using a Nanodrop1000 (Thermo
scientific) for all samples. Ethics approval for the human
tissue studies was from the University of New South Wales
Human Research Ethics Committee.
Frozen mouse brain samples from LRRK2 knockout
C57BL/6J adult mice and age-matched controls were kindly
provided by Dr. Mark Cookson and Dr. Iakov Rudenko (NIH
(NIA), Bethesda, MD, USA). Mouse brain tissue was lysed in
RIPA buffer (25 mM Tris–HCl pH7.6; 150 mM NaCl; 0.1 %
SDS; 1 %NP40) supplemented with protease and phosphatase
inhibitor cocktails (Roche diagnostics, Mannheim, Germany)
using a mechanic homogenizer. Lysates were incubated in a
rotor for 1 h at 4 °C and then sonicated. Following centrifuge
separation (at 10,000×g for 10 min at 4 °C), the supernatants
were kept and total protein concentration quantified using
BCA assay (Thermo Fisher Scientific, Rockford, IL, USA).
Immunoprecipitation and western blot analyses
Immunoprecipitation experiments were performed using
1 mg (cells) or 6 mg (brain) of total protein. Lysates were
pre-cleared by incubation with 20 μl of protein G beads
(Invitrogen, Barcelona, Spain) for 30 min at 4 °C in rotation.
Supernatants were recovered and incubated with 2 μg of the
corresponding immunoprecipitation antibody: anti-α-
synuclein (C-20, Santa Cruz Biotechnologies, Santa Cruz,
CA, USA), anti-Myc (Cell Signaling, Danvers, MA, USA)
or anti-LRRK2 (c41-2 MJFF), followed by overnight rota-
tion at 4 °C. The next day, 40 μl of protein G beads were
added for 3 h in a rotator at 4 °C. Beads were washed 5×
with immunoprecipitation buffer, then re-suspended in 20 μl
of protein sample buffer (50 mM Tris–HCl pH6.8; 2 %
SDS; 10 % glycerol; 1 % β-mercaptoethanol; 0.02 % bro-
mophenol blue) and boiled at 95 °C for 5 min. Supernatants
were resolved on 12 % SDS-PAGE gels. Proteins were
transferred overnight to nitrocellulose membranes and
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blocked in 5 % non-fat dry milk in TBS-Tween for 1 h. The
membranes were incubated overnight at 4 °C with the
primary antibodies using the following dilutions: anti-α-
synuclein (syn-1, BD Biosciences, San Jose, CA, USA,
1:1,000), anti-Myc (Cell Signaling, Danvers, MA, USA,
1:4,000) and anti-LRRK2 (c41-2 MJFF, 1:1,000). Immuno-
blots were washed with TBS-Tween and incubated for 1 h at
room temperature with the corresponding HRP-labelled sec-
ondary antibody (GE Healthcare, Bucks, UK, 1:10,000).
Immunoreactivity was visualised by chemiluminescence us-
ing an ECL detection system (Millipore, Billerica, MA,
USA) and subsequent exposure to autoradiographic film.
Standard Western blotting was used to assess the relative
amounts of LRRK2 [14] and α-synuclein [15] in 25 μg of
the TBS-soluble protein from human brain samples com-
pared with β-actin (loading control). The following primary
antibodies were used: LRRK2 (c41-2, MJFF, 1:1,000), anti-
α-synuclein (syn-1, BD Biosciences, San Jose, CA, USA,
1:2,000), anti-S129 phosphorylated α-synuclein (Elan Phar-
maceuticals Inc. [16], 1:10,000 or WAKO, Richmond, VA,
USA, 1:10,000) and anti-mouse β-actin (Sapphire Bioscien-
ces, Waterloo, Australia, 1:10,000). LRRK2 protein was
separated on pre-cast NuPAGE 3–8 % gradient Tris–acetate
gels (Invitrogen, Carlsbad, CA, USA) with constant voltage
of 150 V for 50 min, and transferred onto polyvinylidene
difluoride membranes (BioRad Laboratories, Hercules, CA,
USA) at 30 V constant for 2 hours. α-Synuclein and S129
phosphorylated α-synuclein was separated on 12 % SDS-
PAGE gels with constant voltage of 100 V for 90 min, and
transferred onto 0.22-μm nitrocellulose membranes (Bio-
Rad Laboratories, Hercules, CA, USA) at 75 V constant
for 45 min. To normalise the data between the different gels,
the same control sample was loaded on all gels and probed
for β-actin in addition to the proteins of interest. Immuno-
reactivity was visualised by chemiluminescence using an
ECL detection system (GE Healthcare Biosciences, Pitts-
burgh, PA, USA) and the intensity of each band quantified
using ImageJ software (http://rsbweb.nih.gov/ij/) with the
relative expression normalised to the β-actin of the internal
standard. Multivariate linear regression analysis (SPSS
IBM, New York, NY, USA) was used to identify any differ-
ences in protein levels between groups and regions, and
linear regression modelling (SPSS IBM, New York, NY,
USA) was used to determine if LRRK2 and α-synuclein
protein levels were related to each other and could predict
group status. Age and post-mortem interval were co-
factored into all analyses. The mean difference and standard
error are given for all values.
Routine cell culture, plasmids and transfections
Both wild-type (WT) and G2019S forms of LRRK2 plas-
mids (pCMV-Tag3B-2xMyc-LRRK2, a kind gift from Dr.
Mark Cookson, NIH (NIA), Bethesda, MD, USA) and WT
pSI-α-synuclein plasmids (a kind gift from Dr. Bradley
Hyman, Massachusetts General Hospital, USA) were used
to over-express proteins for co-immunoprecipitation
experiments.
Human embryonic kidney 293 cells (HEK-293) were
cultured in DMEM media (Invitrogen, Barcelona, Spain)
supplemented with 10 % foetal bovine serum and 1 %
penicillin–streptomycin in 5 % CO2 at 37 °C. One day
before transfection, 1.5×106cells were seeded in 10-cm
plates. Cells were transiently transfected using a total of
6 μg of plasmid DNA using FuGENE®6 (Roche diagnos-
tics, Mannheim, Germany). Forty-eight hours later, cells
were washed with PBS, harvested in immunoprecipitation
buffer supplemented with protease and phosphatase inhib-
itors and sonicated. Lysates were centrifuged at 10,000×g
for 10 min at 4 °C. Pellets were discarded and the total
protein concentration of the supernatants quantified using
BCA assay (Pierce).
α-Synuclein aggregation model in H4 cells
A gene construct encoding for tagged version of α-
synuclein (SynT, a kind gift from Dr. Bradley Hyman,
Massachusetts General Hospital, USA) was co-transfected
with the synphilin-1 into H4 cells to recreate Lewy body-
like inclusions, as previously described [17]. Briefly, H4
cells were cultured in OPTIMEM media (Gibco, Invitrogen,
Barcelona, Spain) supplemented with 10 % of foetal bovine
serum and 1 % of penicillin-streptomycin in an atmosphere
of 37 °C and 5 % CO2. Twenty-four hours before the
transfection, 2.0×105cells were seeded in a 35-cm dish
(Ibidi, Munich, Germany). Cells were transfected with
2 μg of each synphilin-1 and SynT plasmids using
FuGENE®6 (Roche diagnostics, Mannheim, Germany). Af-
ter transfection, cells were maintained for 48 h prior to
further manipulations. H4 cells with reduced LRRK2 ex-
pression were created using lentiviral particles encoding
LRRK2 shRNAs or a control scramble shRNA sequence
(see Supplementary Information) and the model for α-
synuclein inclusions (described above) recreated in H4-
LRRK2 knockdown cell lines.
Confocal microscopy in cells and tissue sections
LRRK2 and α-synuclein localization was performed in hu-
man tissue sections of the midbrain and anterior cingulate
cortex and in transfected H4 cells with and without shRNA
knockdown of LRRK2 expression. In the human tissue
sections, both routine peroxidase immunohistochemistry
and double immunofluorescence were performed. In H4
cells, single and double immunofluorescence were
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performed. Details of experiments showing antibody speci-
ficity are provided in Supplementary Information.
Adjacent human sections were pre-treated with 99 %
formic acid for 3 min and citrate buffer (pH6.0) for 3 min,
then incubated sequentially with anti-LRRK2 (MJFF c41-2,
1:200 and L955 Abgent, 1:500), anti-α-synuclein (BD Bio-
sciences, San Jose, CA, USA, 1:200) and anti-S129 phos-
phorylated α-synuclein (Elan Pharmaceuticals Inc. [16],
1:10,000) antibodies, biotinylated secondary antibodies (an-
ti-mouse IgG for α-synuclein and anti-rabbit IgG for
LRRK2; Vector, Burlingame, CA, USA), and then the avi-
din–biotin complex (Vectastain Elite ABC Kit, Vector, Bur-
lingame, CA, USA) prior to visualisation with DAB
substrate (Sigma, St. Louis, MO, USA) in 0.1 % H2O2.
Sections were counterstained with cresyl violet.
LRRK2 and α-synuclein were co-localized in human
sections and the H4 cell α-synuclein aggregation model
using double immunofluorescence. Briefly, cells were
washed, fixed with 4 % PFA, permeabilized with 0.5 %
Triton, blocked with 1.5 % normal goat serum, then incu-
bated in anti-α-synuclein (BD Biosciences, San Jose, CA,
USA, 1:1,000) and anti-LRRK2-2 (MJFF c41-2, 1:50) anti-
bodies, while human sections were pre-treated as above and
incubated with anti-α-synuclein (BD Biosciences, San Jose,
CA, USA, 1:200) and anti-LRRK2 (L955 Abgent, 1:500)
antibodies or with anti-S129 phosphorylated α-synuclein
(Elan, 1:10,000) and anti-LRRK2 (L955 Abgent, 1:500)
antibodies. Then, a cocktail of secondary antibodies was
used: for α-synuclein and S129 phosphorylated α-
synuclein anti-mouse IgG conjugated with Alexa Fluor
488 (Molecular probes, Eugene, OR, USA, 1:500) and for
LRRK2 anti-rabbit IgG conjugated with Alexa Fluor 568
(Molecular Probes, 1:250). Fluorescent images were cap-
tured either using a Nikon Microscope ECLIPSE 90i con-
focal microscope (for human tissue sections) or using a
Leica Microsystems confocal microscope (for H4 cells).
The proportion of neurons in the human brain sections
that co-localized LRRK2 and α-synuclein was quantified in
each section (total number of LRRK2 positive neurons/the
total number of α-synuclein positive neurons) and double
labelling of Lewy bodies assessed (average number sampled/
section varied from 1 to 63, depending on the region
assessed). Pearson correlation coefficients were used to de-
termine whether there was any relationship between the
numbers of Lewy bodies containing α-synuclein and those
also containing LRRK2 in the PD cases examined. Quanti-
fication of the aggregation pattern of α-synuclein inclusions
in H4 cells was performed. Briefly, for each condition (con-
trol and LRRK2-KD), a total of 40–60 cells containing α-
synuclein inclusions were analysed, and a total of three
independent experiments were performed. Cells were classi-
fied into two groups: cells with <5 inclusions and cells with
≥5 inclusions, and the results were expressed as a percentage
of the total number of cells with inclusions. The average size
of inclusions per cell was also quantified using the ImageJ
software (http://rsbweb.nih.gov/ij/).
Results
Co-immunoprecipitation of LRRK2 and α-synuclein
In order to investigate the interaction between LRRK2 and
α-synuclein, we used mouse brain samples from WT and
LRRK2 knockout animals. The immunoprecipitation of α-
synuclein from mouse brain lysates pulled down LRRK2 in
WT samples, but not in knockout samples (Fig. 1a). We also
verified the interaction between LRRK2 and α-synuclein
when the immunoprecipitations were performed in human
brain lysates (data not shown).
In order to investigate whether LRRK2 mutations alter
the interaction with α-synuclein, we over-expressed WT or
G2019S mutant LRRK2 together with α-synuclein in
HEK-293 cells. Immunoprecipitation of LRRK2 from cells
over-expressing Myc-LRRK2 (WT or G2019S mutant)
together with α-synuclein pulled down α-synuclein
(Fig. 1b). Consistently, when α-synuclein was immunopre-
cipitated, the LRRK2 proteins (WT and G2019S) were also
co-immunoprecipitated (Fig. 1c). We did not find signifi-
cant alterations in the pattern of co-immunoprecipitation
between WT and G2019S mutant, indicating that the inter-
action between the two proteins is not disturbed by this
mutation.
Co-localization of LRRK2 and α-synuclein in PD brain
and cell model
PD brain samples were examined to determine whether
LRRK2 and α-synuclein or phosphorylated α-synuclein
were co-localized. We found that LRRK2 increases along
with α-synuclein in neurons prior to Lewy body formation
(Fig. 2a) as well as depositing in some but not all of the
hallmark inclusions (Fig. 2b–d). LRRK2 was also observed
in phosphorylated α-synuclein-immunoreactive inclusions,
often centralized to a radiating pattern of phosphorylated α-
synuclein fibrils (Fig. 2f–h). Quantitation of the numbers of
α-synuclein inclusions immunopositive for LRRK2 in ten
PD cases (Table 1) indicates that 60 % of cingulate Lewy
bodies and 43 % of nigral Lewy bodies contained both
proteins (Fig. 2b, c). The specificity of the co-localization
can be taken as genuine, as no 280-kDa LRRK2 band was
detected on Western blot and no immunoreactivity in tissue
sections in peptide pre-absorption experiments (see Supple-
mentary Figure). There was no correlation between the
number of α-synuclein-positive Lewy bodies and those also
containing LRRK2 across the cases examined.
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We also interrogated an in vitro model that reproduces
the formation of α-synuclein inclusions in H4 cells [17].
Using this model, we observed co-localization of endoge-
nous LRRK2 with the α-synuclein-positive inclusions
(Fig. 2e).
Knocking down LRRK2 expression reduces α-synuclein
aggregation
To further investigate the effect of LRRK2 on α-
synuclein aggregation, LRRK2 expression was knocked
down using shRNAs in the H4 cell model. Knocking
down LRRK2 expression did not produce significant
changes in endogenous α-synuclein or phosphorylated
α-synuclein levels (Fig. 3a). Transiently transfecting
these LRRK2-deficient cells with SynT and synphilin-1
expression plasmids showed that LRRK2 silencing sig-
nificantly increased the number and decreased the size
of α-synuclein inclusions resulting in a greater number
of cells bearing smaller α-synuclein inclusions
(Fig. 3b–d).
Fig. 2 Co-localization of LRRK2 and α-synuclein in PD brain and
cell models. In PD brains (a–d, f–g), merged images clearly outline
single neurons in the substantia nigra (a, b) and Lewy bodies (b–d, f–
g) using double-labelling immunofluorescence. There is an increase of
LRRK2 and α-synuclein immunoreactivity in brainstem neurons with-
out Lewy body formation (a), with LRRK2 co-localizing with α-
synuclein in Lewy bodies (donut inclusion in b) in these neurons.
The co-localisation of LRRK2 and α-synuclein was also observed in
cortical Lewy bodies (c). Cortical Lewy bodies without LRRK2 im-
munoreactivity were also observed (d). S129 phosphorylated α-
synuclein antibody also confirmed co-localisation of LRRK2 with
phosphorylated α-synuclein, with LRRK2 often centralized to a radi-
ating pattern of phosphorylated α-synuclein fibrils (f–h). In the H4 cell
model, double-labelling immunofluorescence for α-synuclein inclu-
sion formation shows that endogenous LRRK2 co-localizes with α-
synuclein inclusions (e). Scales in all panels are equivalent to 10 μm
Fig. 1 Co-immunoprecipitation of LRRK2 and α-synuclein. a West-
ern blots showing the immunoprecipitation of endogenous α-synuclein
in lysates from WT and LRRK2 knockout mouse brains. The co-
immunoprecipitation with endogenous LRRK2 occurs in WT but not
in the LRRK2 knockout brain sample. b, c Over-expression of Myc-
LRRK2 (WT or G2019S) together with α-synuclein in HEK-293 cells
showed the co-immunoprecipitation of LRRK2 (WT or G2019S) with
α-synuclein using anti-Myc as the capture antibody and anti-α-
synuclein and anti-LRRK2 antibodies for Western blotting (b) or using
anti-α-synuclein as the capture antibody and anti-α-synuclein and anti-
Myc antibodies for Western blotting (c)
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Correlations between the levels of α-synuclein and LRRK2
in PD
To explore the relationship between protein levels of
LRRK2 and α-synuclein in PD, 20 cases (controls and
Braak PD stages IV and V, Supplementary Table) were
analysed. Multivariate analysis factoring in age and post-
mortem delay showed that the levels of total and phosphor-
ylated α-synuclein were significantly increased over control
levels only in PD brain regions with Lewy bodies (p<0.001).
In the cases examined, all stage IV cases had high Lewy
body densities in the amygdala (Fig. 4a), while significant
densities of cingulate Lewy bodies were observed in all stage
V cases (Fig. 4b). No Lewy bodies were seen in the visual
cortex of any case, although very small phosphorylated
deposits were observed in stage V cases (Fig. 4c). In PD,
there was a substantial 220±20 % increase over controls in
α-synuclein protein levels in the amygdala and a less sub-
stantial 48±6 % increase in the cingulate cortex, with no
change in the visual cortex (Fig. 4d, e). This pattern of
regional increase in α-synuclein levels was even more strik-
ing when assessing phosphorylated α-synuclein protein lev-
els (p00.01), as very low levels of phosphorylated α-
synuclein were observed across all regions in controls com-
pared to PD (Fig. 4e). There was a very large 60±18-fold
increase in phosphorylated α-synuclein protein levels in the
PD amygdala, a 32±4-fold increase in the PD cingulate
cortex and an 8±3-fold change in the PD visual cortex
relative to controls (Fig. 4d, e).
The expression of LRRK2 was analysed using the same
methods in the same brain extracts (Fig. 5). Multivariate
analysis co-varying for age or post-mortem delay showed
that the levels of LRRK2 were increased in PD compared
with controls in regions containing Lewy bodies (p<0.04),
with no difference between the LRRK2 levels in these Lewy
body-containing regions (p00.6). Within these regions,
there was a small but significant 23±6 % increase over
controls in full-length LRRK2 levels (Fig. 5a, b).
To determine the relationship between LRRK2 and
α-synuclein levels and PD, linear regression modelling was
used assessing the protein levels obtained in the amygdala and
cingulate cortex. This analysis revealed that increasing levels
of LRRK2 and total and phosphorylated α-synuclein corre-
lated with each other in PD but not controls (Fig. 5c, p<0.001,
β coefficients00.27, 0.33 and 0.37, respectively).
Discussion
Mutations in LRRK2 and α-synuclein proteins are known to
be responsible for autosomal dominant forms of PD [2]. Due
to the growing interest in the potential interaction of these
proteins in the pathogenesis of PD [10, 18], we investigated
such an interaction using a variety of techniques. Co-
immunoprecipitation showed that endogenous LRRK2 and
α-synuclein interact in cells, mouse and human brain tissue.
We also confirmed this interaction in over-expression stud-
ies in HEK-293 cells. In this model, we found that the
G2019S mutation did not alter the ability of LRRK2 to
interact with α-synuclein. Nevertheless, we cannot exclude
that the interaction with G2019S is not potentiated due to
the over-expression of the protein in HEK cells. The
G2019S mutation is located in the kinase domain of
Fig. 3 Knockdown of LRRK2 expression alters the size and number
of α-synuclein inclusions. a Western blots showing that H4 cells
infected with LRRK2-shRNA have the expected knockdown of
LRRK2 protein (LRRK2-KD) compared with the scramble shRNA
control, but have no significant change on the level of endogenous
α-synuclein or phosphorylated α-synuclein at S129. b The model for
α-synuclein inclusions was reproduced in a LRRK2 knockdown cell
line and in parental control cells. Cells were classified into two groups
according to the number of α-synuclein-immunoreactive inclusions
observed: cells with five or more inclusions and cells with less than
five inclusions. Scale bar010 μm. c Data from three independent
experiments shows a greater proportion of cells containing five or
more inclusions in the LRRK2 knockdown cells compared with con-
trols. d LRRK2 silencing (LRRK2-KD) promotes a significant reduc-
tion in the average size of the inclusions, resulting in a more punctate
aggregation pattern in the cells. Student’s test (n03; **p<0.01). Error
bars0SEM
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LRRK2, and shows an enhanced kinase activity compared
to WT LRRK2 [19]. Our data indicate that the kinase
domain and therefore the phosphorylation capacity of
LRRK2 do not play a large role in its interaction with
α-synuclein. This is consistent with recent evidence show-
ing that the levels of rather than mutations in LRRK2 are
related to the deposition of neuropathology [20]. Overall,
these results unequivocally demonstrate, for the first time, a
definite interaction between endogenous LRRK2 and
α-synuclein, a finding that had only been detected under
pathological and oxidative stress conditions [11].
In human PD brains, we show co-localization of LRRK2
and α-synuclein as well as S129 phosphorylated α-
synuclein in Lewy bodies and also co-localization in neu-
rons that have not formed Lewy bodies in Lewy body-
producing regions. We have also replicated this co-
localization of LRRK2 and α-synuclein in an established
cell model for α-synuclein inclusion formation. Of interest,
our quantitation in the PD cases showed that LRRK2 co-
localized in more cortical compared with brainstem Lewy
bodies. According to Braak PD staging [12], cortical Lewy
bodies develop later in PD, further suggesting an early
association between LRRK2 and α-synuclein in Lewy body
formation. In these neurons, S129 phosphorylated α-
synuclein fibrils often appeared to radiate from more cen-
tralized LRRK2 within Lewy bodies. Overall, our results
suggest that the interaction between LRRK2 and α-
synuclein or S129 phosphorylated α-synuclein is enhanced
prior to and during the formation of α-synuclein aggrega-
tion and fibrilization. These data are also consistent with
other studies in brain tissue showing the co-localization of
LRRK2 in α-synuclein-immunoreactive Lewy bodies
[21–23], although questions regarding the specificity of
the different LRRK2 antibodies used have been raised [24,
25]. While variance in the numbers of Lewy bodies co-
localizing LRRK2 may be due to the age of the Lewy bodies
assessed (see above) and account for some of the differ-
ences described in the literature, we are certain of the
specificity of the antibodies used in the current study, as
a number of specificity experiments confirmed that the
protein we localized to early forming Lewy bodies was
LRRK2 (see Supplementary Figure).
To test this association further, we knocked down
LRRK2 in a cell model of α-synuclein inclusion formation
and found that reduced LRRK2 expression altered α-
synuclein inclusions, resulting in an increased number of
smaller inclusions per cell. In this model, α-synuclein is co-
expressed and co-aggregates with synphilin-1, as observed
in Lewy bodies [26, 27]. Synphilin-1 recruits and binds
α-synuclein leading to inclusion formation [26], and
synphilin-1 and 14-3-3 proteins accumulate with mutant
α-synuclein in A53T transgenic mice [28]. While there is
little indication that synphilin-1 closely associates with
LRRK2, 14-3-3 proteins are not only known to interact with
and stabilise phosphorylated LRRK2 [29] but also have a
preference for binding S129 phosphorylated α-synuclein
Fig. 4 Increased levels of total and S129 phosphorylated α-synuclein
in PD brain. a–c Peroxidase immunohistochemistry of brain sections
from the same PD case showing the regional density of Lewy pathol-
ogy as revealed by immunohistochemistry using phosphorylated α-
synuclein antibody and counterstained with cresyl violet. Scale in c0
100 μm and is equivalent for a and b. Severe pathology is observed in
the amygdala (a) with moderate pathology in the anterior cingulate
cortex (b). Neuronal inclusions are not observed in the visual cortex
(c). d, e Quantitation (d) of Western blots (e) in the same three brain
regions in the PD cases (represented as an increase over control levels)
confirmed the regional changes noted histologically in PD and showed
considerably more phosphorylated α-synuclein compared with total α-
synuclein in each regions (note the percentage at left versus fold
change at right in d). Error bars0SEM
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[30] and accumulate in Lewy bodies [31]. 14-3-3 proteins
and α-synuclein have opposing effects on regulating the
activity of many enzymes [31], and such regulation may
occur within a complex associated with LRRK2. The mi-
crotubule binding protein tau phosphorylation complex has
been shown to require both 14-3-3 and α-synuclein [32, 33],
and it is of interest that over-expression of tau has a similar
effect on the formation of α-synuclein inclusions in this
cellular model [34] to the knockdown of LRRK2 (present
study), as well as sequestering phosphorylated tau into the
inclusions [34]. Either reducing the amount of unbound α-
synuclein by enhanced recruitment into the tau phosphory-
lation complex and/or increased tau partnering of 14-3-3 to
shift its binding from and decrease the phosphorylation and
activity of LRRK2, would seem to produce similar effects
on the formation of α-synuclein inclusions in this cellular
model of inclusion formation. In mouse models, LRRK2
over-expression enhances the progression of α-synuclein-
mediated neuropathological changes, and LRRK2 deletion
delays the progression of pathology [20]. All of these data
are consistent with an interaction between LRRK2 and
α-synuclein in patients with PD.
This is the first study showing correlations between the
relative protein levels of LRRK2 and phosphorylated and
total α-synuclein in PD human brain tissue extracts, but not
in controls. A small increase in the levels of LRRK2 in the
brain tissue from PD patients directly correlated with much
larger regional increases in α-synuclein levels, and more
strikingly with a widespread α-synuclein S129 phosphory-
lation. In cell models, an increase in LRRK2 expression
significantly increases α-synuclein mRNA [35], and elevat-
ed α-synuclein mRNA levels are co-regulated with in-
creased LRRK2 transcription [36]. The positive feedback
in turn activates the ERK signalling pathway leading to
phosphorylation of α-synuclein [35]. It is of interest that
in long-duration PD cases, the gene expression levels of
both LRRK2 [37] and α-synuclein [38] are decreased in
multiple brain regions forming Lewy bodies. This is possi-
bly as a self-protective mechanism to the high levels of these
proteins that accumulate within neurons in these regions,
and suggests that deficits in protein degradation mecha-
nisms play a significant role in the progression of pathology
overtime.
Beyond the endogenous interaction of LRRK2 and
α-synuclein that we have shown in this study, we are still
not able to determine whether the nature of LRRK2 inter-
action with α-synuclein is a direct protein–protein binding
or an indirect binding within a protein complex. As it has
been extensively suggested, LRRK2 interacts with other
proteins also implicated in PD to form protein complexes
[10, 18, 20, 29, 37, 39]. While a fine analysis of the molec-
ular determinants of the interaction between LRRK2 and α-
synuclein is still required, our study has unequivocally
established that there is an interaction between LRRK2
and α-synuclein, and that this interaction appears to be
enhanced in patients with PD and in cell models of α-
synuclein inclusion formation. Importantly, we also provide
evidence showing that the levels of LRRK2 impact on α-
synuclein pathology, consistent with studies in animal mod-
els of PD [20]. Ultimately, our work paves the way for the
understanding of the molecular interplay between two cen-
tral players in PD.
Fig. 5 LRRK2 levels correlated with α-synuclein levels in PD brain.
Quantitation (a) of LRRK2 Western blots (b) in the same brain regions
in the PD cases (represented as an increase over control levels) and
correlations with α-synuclein levels (c). The protein levels of LRRK2
were increased in the disease-affected areas (amygdala and cingulate)
compared to the non-affected area (visual cortex) (a). Error bars0
SEM. Multivariate analysis revealed a significant correlation between
the increasing levels of α-synuclein and LRRK2 only in PD but not
controls (c)
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